Literature DB >> 2548087

Regulation of the visna virus long terminal repeat in macrophages involves cellular factors that bind sequences containing AP-1 sites.

D H Gabuzda1, J L Hess, J A Small, J E Clements.   

Abstract

Visna virus gene expression is highly restricted in monocytes but is induced by monocyte-macrophage differentiation in vivo. Deletion and linker-scanning mutants, gel shift assays, and DNase I footprinting were used to identify sequences in the visna virus long terminal repeat involved in the developmental regulation of gene expression in the U937 monocytic cell line. We found that an AP-1 and an AP-4 binding site were critical for basal activity and that the AP-1 site was required for phorbol ester-inducible gene expression. These results suggest that cellular factors that interact with AP-1 sites are involved in the developmental regulation of visna virus gene expression in macrophages.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548087      PMCID: PMC362346          DOI: 10.1128/mcb.9.6.2728-2733.1989

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  38 in total

1.  Splicing of in vitro synthesized messenger RNA precursors in HeLa cell extracts.

Authors:  N Hernandez; W Keller
Journal:  Cell       Date:  1983-11       Impact factor: 41.582

Review 2.  Lentiviral diseases of sheep and goats: chronic pneumonia leukoencephalomyelitis and arthritis.

Authors:  O Narayan; L C Cork
Journal:  Rev Infect Dis       Date:  1985 Jan-Feb

Review 3.  The role of protein kinase C in cell surface signal transduction and tumour promotion.

Authors:  Y Nishizuka
Journal:  Nature       Date:  1984 Apr 19-25       Impact factor: 49.962

4.  The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection.

Authors:  C M Gorman; G T Merlino; M C Willingham; I Pastan; B H Howard
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

5.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

6.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

7.  Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus.

Authors:  M A Gonda; F Wong-Staal; R C Gallo; J E Clements; O Narayan; R V Gilden
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

8.  The visna virus long terminal repeat directs expression of a reporter gene in activated macrophages, lymphocytes, and the central nervous systems of transgenic mice.

Authors:  J A Small; C Bieberich; Z Ghotbi; J Hess; G A Scangos; J E Clements
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

9.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

10.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

View more
  25 in total

1.  Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity.

Authors:  C Van Lint; C A Amella; S Emiliani; M John; T Jie; E Verdin
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  The intragenic enhancer of human immunodeficiency virus type 1 contains functional AP-1 binding sites.

Authors:  C Van Lint; A Burny; E Verdin
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

3.  Visna virus-induced activation of MAPK is required for virus replication and correlates with virus-induced neuropathology.

Authors:  Sheila A Barber; Linda Bruett; Brian R Douglass; David S Herbst; M Christine Zink; Janice E Clements
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Comparison of the transcriptional activity of the long terminal repeats of simian immunodeficiency viruses SIVmac251 and SIVmac239 in T-cell lines and macrophage cell lines.

Authors:  M G Anderson; J E Clements
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

Review 5.  Lentiviruses are etiological agents of chronic diseases in animals and acquired immunodeficiency syndrome in humans.

Authors:  O Narayan
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

6.  Inhibition of lymphoproliferation and protein kinase C by synthetic peptides with sequence identity to the transmembrane and Q proteins of visna virus.

Authors:  C L Ruegg; J E Clements; M Strand
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice.

Authors:  S Bellosta; R W Mahley; D A Sanan; J Murata; D L Newland; J M Taylor; R E Pitas
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study.

Authors:  V G Valcour; B T Shiramizu; P Sithinamsuwan; S Nidhinandana; S Ratto-Kim; J Ananworanich; U Siangphoe; J H Kim; M de Souza; V Degruttola; R H Paul; C M Shikuma
Journal:  Neurology       Date:  2009-03-17       Impact factor: 9.910

9.  Targeting of the visna virus tat protein to AP-1 sites: interactions with the bZIP domains of fos and jun in vitro and in vivo.

Authors:  B A Morse; L M Carruth; J E Clements
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  Visna virus Tat protein: a potent transcription factor with both activator and suppressor domains.

Authors:  L M Carruth; J M Hardwick; B A Morse; J E Clements
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.